P3 Health Partners Inc. filings document the public-company reporting record for a population health management business and its Nasdaq-listed warrants exercisable for Class A common stock. Proxy statements cover annual meeting matters and corporate governance, while Form 8-K reports describe material agreements, amendments to debt instruments, unregistered equity securities, charter or bylaw matters and Nasdaq stockholders’ equity compliance topics.
The filing record also includes disclosures involving P3 Health Group, LLC and service arrangements under the company’s Care Enablement Model, including clinical, operational and data-driven support for primary care providers in Medicare Advantage networks.
P3 Health Partners Inc. reports actions taken to regain compliance with Nasdaq’s stockholders’ equity requirement under Listing Rule 5550(b)(1), which sets a minimum of $2.5 million in equity. The company undertook a major balance sheet recapitalization.
On April 27, 2026, about $252,479,967 of outstanding promissory notes, including principal, accrued interest and back-end fees, were exchanged into non-convertible, non-voting, non-listed preferred stock. In addition, affiliates of Chicago Pacific Founders agreed to purchase up to $70.0 million of units consisting of Series D 19.5% Cumulative Preferred Stock and warrants, of which $30.0 million of units had been sold.
The unaudited pro forma balance sheet shows long-term debt falling from $259,569 thousand to $63,907 thousand and total stockholders’ equity shifting from a deficit of $(143,548) thousand to positive equity of $82,114 thousand. The company believes it now satisfies Nasdaq’s stockholders’ equity requirement, though Nasdaq will continue to monitor ongoing compliance.
P3 Health Partners Inc. reports actions taken to regain compliance with Nasdaq’s stockholders’ equity requirement under Listing Rule 5550(b)(1), which sets a minimum of $2.5 million in equity. The company undertook a major balance sheet recapitalization.
On April 27, 2026, about $252,479,967 of outstanding promissory notes, including principal, accrued interest and back-end fees, were exchanged into non-convertible, non-voting, non-listed preferred stock. In addition, affiliates of Chicago Pacific Founders agreed to purchase up to $70.0 million of units consisting of Series D 19.5% Cumulative Preferred Stock and warrants, of which $30.0 million of units had been sold.
The unaudited pro forma balance sheet shows long-term debt falling from $259,569 thousand to $63,907 thousand and total stockholders’ equity shifting from a deficit of $(143,548) thousand to positive equity of $82,114 thousand. The company believes it now satisfies Nasdaq’s stockholders’ equity requirement, though Nasdaq will continue to monitor ongoing compliance.
P3 Health Partners Inc. reported Q1 2026 operating revenue of $386.4M, up from $373.2M a year earlier, driven mainly by capitated Medicare Advantage contracts. Medical expense fell sharply, turning operating results from a loss to operating income of $8.2M.
The company posted net income of $3.0M versus a prior-year net loss of $44.2M, and Adjusted EBITDA improved to $25.8M from a loss of $22.2M. However, it still used $27.5M of cash in operating activities, had a working capital deficit of $353.3M, stockholders’ deficit of $143.5M, and long-term debt of $379.3M at double‑digit interest rates.
Management states that substantial doubt exists about the company’s ability to continue as a going concern without additional financing or other actions. After quarter‑end, P3 exchanged about $252.5M of related‑party promissory notes into new preferred stock and raised $30.0M of additional preferred capital with attached warrants, while up to $40.0M more preferred funding remains available under the purchase agreement.
P3 Health Partners Inc. reported Q1 2026 operating revenue of $386.4M, up from $373.2M a year earlier, driven mainly by capitated Medicare Advantage contracts. Medical expense fell sharply, turning operating results from a loss to operating income of $8.2M.
The company posted net income of $3.0M versus a prior-year net loss of $44.2M, and Adjusted EBITDA improved to $25.8M from a loss of $22.2M. However, it still used $27.5M of cash in operating activities, had a working capital deficit of $353.3M, stockholders’ deficit of $143.5M, and long-term debt of $379.3M at double‑digit interest rates.
Management states that substantial doubt exists about the company’s ability to continue as a going concern without additional financing or other actions. After quarter‑end, P3 exchanged about $252.5M of related‑party promissory notes into new preferred stock and raised $30.0M of additional preferred capital with attached warrants, while up to $40.0M more preferred funding remains available under the purchase agreement.
P3 Health Partners reported a sharp improvement in results for the quarter ended March 31, 2026. Total revenue was $386.4 million, up 4% year over year, as per-member revenue rose 14% helped by contract restructuring, rate progression, and illness-burden performance.
The company generated medical margin of $73.7 million, or $231 per member per month, and turned to net income of $3.0 million from a $44.2 million loss a year earlier. Adjusted EBITDA reached $25.8 million, or $81 PMPM, versus a prior-year adjusted EBITDA loss.
At-risk membership was about 106,000 members, down 10% as the company intentionally rationalized its network and payers. Reflecting stronger performance, management raised full-year 2026 adjusted EBITDA guidance to a midpoint of $40 million, within a range of $20–$60 million, on projected revenue of $1.5–$1.65 billion.
P3 Health Partners reported a sharp improvement in results for the quarter ended March 31, 2026. Total revenue was $386.4 million, up 4% year over year, as per-member revenue rose 14% helped by contract restructuring, rate progression, and illness-burden performance.
The company generated medical margin of $73.7 million, or $231 per member per month, and turned to net income of $3.0 million from a $44.2 million loss a year earlier. Adjusted EBITDA reached $25.8 million, or $81 PMPM, versus a prior-year adjusted EBITDA loss.
At-risk membership was about 106,000 members, down 10% as the company intentionally rationalized its network and payers. Reflecting stronger performance, management raised full-year 2026 adjusted EBITDA guidance to a midpoint of $40 million, within a range of $20–$60 million, on projected revenue of $1.5–$1.65 billion.
P3 Health Partners Inc. is calling a fully virtual 2026 annual stockholder meeting on June 9, 2026. Holders of Class A and Class V common stock as of April 10, 2026, totaling 3,318,290 Class A shares and 3,919,124 Class V shares, may vote.
Stockholders will elect three Class II directors, ratify BDO USA, P.C. as auditor, cast an advisory say‑on‑pay vote, and decide whether to approve the potential issuance of up to 3,341,130 Class A shares upon exercise of warrants held by VBC Growth SPV 5, LLC.
The warrants were issued alongside a Promissory Note providing up to $70 million of funding to subsidiary P3 Health Group, LLC, bearing 19.5% annual interest and various upfront and back-end fees. The proxy also details board structure, committee work, executive pay, and 2025 audit fees of $2,003,400.
P3 Health Partners Inc. is calling a fully virtual 2026 annual stockholder meeting on June 9, 2026. Holders of Class A and Class V common stock as of April 10, 2026, totaling 3,318,290 Class A shares and 3,919,124 Class V shares, may vote.
Stockholders will elect three Class II directors, ratify BDO USA, P.C. as auditor, cast an advisory say‑on‑pay vote, and decide whether to approve the potential issuance of up to 3,341,130 Class A shares upon exercise of warrants held by VBC Growth SPV 5, LLC.
The warrants were issued alongside a Promissory Note providing up to $70 million of funding to subsidiary P3 Health Group, LLC, bearing 19.5% annual interest and various upfront and back-end fees. The proxy also details board structure, committee work, executive pay, and 2025 audit fees of $2,003,400.
P3 Health Partners Inc. entered a major restructuring with its largest investor, Chicago Pacific Founders, to help regain compliance with Nasdaq’s stockholders’ equity requirement. About $252.48 million of promissory note debt will be exchanged into several series of non‑convertible, non‑voting cumulative preferred stock with a $100 stated value per share.
The company also agreed to sell up to $70 million of additional preferred-stock-and-warrant units, of which $10 million closed initially. The new preferred ranks senior to all common stock, carries dividend rates up to 19.5%, and is paired with long-dated warrants for Class A common shares.
P3 Health Partners Inc. entered a major restructuring with its largest investor, Chicago Pacific Founders, to help regain compliance with Nasdaq’s stockholders’ equity requirement. About $252.48 million of promissory note debt will be exchanged into several series of non‑convertible, non‑voting cumulative preferred stock with a $100 stated value per share.
The company also agreed to sell up to $70 million of additional preferred-stock-and-warrant units, of which $10 million closed initially. The new preferred ranks senior to all common stock, carries dividend rates up to 19.5%, and is paired with long-dated warrants for Class A common shares.
P3 Health Partners Inc. reports significant financial strain in its 2025 annual filing, with management concluding there is substantial doubt about the company’s ability to continue as a going concern. The company ended December 31, 2025 with $25.0 million in unrestricted cash, $336.7 million of debt (including $45.0 million current), and $287.8 million of unpaid claims, after recording a $323.1 million net loss and building an accumulated deficit of $651.1 million.
P3 operates a physician-led, value-based care platform focused on Medicare Advantage, with capitated contracts where four health plans generated about 75% of 2025 revenue. It manages an "Up‑C" structure and owned roughly 46% of P3 Health Group, LLC as of December 31, 2025.
The filing highlights heavy reliance on raising additional capital in 2026, tight debt covenants that required waivers, and regulatory pressure, including California DMHC finding Medcore HP below required tangible net equity and requiring a corrective action plan. P3 also cites risks around California solvency rules, Nasdaq listing compliance, history of losses, and dependence on a few major payors and physician partners.
P3 Health Partners Inc. reports significant financial strain in its 2025 annual filing, with management concluding there is substantial doubt about the company’s ability to continue as a going concern. The company ended December 31, 2025 with $25.0 million in unrestricted cash, $336.7 million of debt (including $45.0 million current), and $287.8 million of unpaid claims, after recording a $323.1 million net loss and building an accumulated deficit of $651.1 million.
P3 operates a physician-led, value-based care platform focused on Medicare Advantage, with capitated contracts where four health plans generated about 75% of 2025 revenue. It manages an "Up‑C" structure and owned roughly 46% of P3 Health Group, LLC as of December 31, 2025.
The filing highlights heavy reliance on raising additional capital in 2026, tight debt covenants that required waivers, and regulatory pressure, including California DMHC finding Medcore HP below required tangible net equity and requiring a corrective action plan. P3 also cites risks around California solvency rules, Nasdaq listing compliance, history of losses, and dependence on a few major payors and physician partners.
P3 Health Partners Inc. reported a new multi-year services arrangement with a large nonprofit health insurer in Nebraska. Through a Statement of Work under an existing Master Services Agreement, P3 will deliver clinical, operational and data-driven support to primary care providers in the insurer’s Medicare Advantage network.
The client will pay management services fees for performance years 2026 and 2027, with the financial structure shifting to a global risk agreement starting in 2028. The Master Services Agreement runs through December 31, 2030 and then renews annually unless either party gives 180 days’ notice.
Both parties have termination rights for material breach, insolvency or change of control, and the client may also terminate on 90 days’ notice if 2026 performance metrics are not met or certain key personnel depart. If the client does not pursue a Medicare Advantage bid for 2027–2028, the Statement of Work ends and the client owes a break-up fee tied to P3’s service and termination-related costs, subject to an agreed cap. P3 will also provide termination assistance services to help transition work back to the client or its designee.
P3 Health Partners Inc. reported a new multi-year services arrangement with a large nonprofit health insurer in Nebraska. Through a Statement of Work under an existing Master Services Agreement, P3 will deliver clinical, operational and data-driven support to primary care providers in the insurer’s Medicare Advantage network.
The client will pay management services fees for performance years 2026 and 2027, with the financial structure shifting to a global risk agreement starting in 2028. The Master Services Agreement runs through December 31, 2030 and then renews annually unless either party gives 180 days’ notice.
Both parties have termination rights for material breach, insolvency or change of control, and the client may also terminate on 90 days’ notice if 2026 performance metrics are not met or certain key personnel depart. If the client does not pursue a Medicare Advantage bid for 2027–2028, the Statement of Work ends and the client owes a break-up fee tied to P3’s service and termination-related costs, subject to an agreed cap. P3 will also provide termination assistance services to help transition work back to the client or its designee.
P3 Health Partners Inc. disclosed that its subsidiary, P3 Health Group, LLC, amended an existing unsecured promissory note with VBC Growth SPV 5, LLC. The amendment extends the availability period for the note’s third funding tranche, keeping the remaining $19.0 million accessible for one or more draws through June 30, 2026. All other terms of the original note dated May 29, 2025 remain unchanged, so this update primarily affects timing of access to already agreed financing rather than the total borrowing capacity.
P3 Health Partners Inc. disclosed that its subsidiary, P3 Health Group, LLC, amended an existing unsecured promissory note with VBC Growth SPV 5, LLC. The amendment extends the availability period for the note’s third funding tranche, keeping the remaining $19.0 million accessible for one or more draws through June 30, 2026. All other terms of the original note dated May 29, 2025 remain unchanged, so this update primarily affects timing of access to already agreed financing rather than the total borrowing capacity.
P3 Health Partners Inc. director filed an amended insider trading report updating their share holdings after receiving a new equity grant. The director was granted 2,000 restricted stock units (RSUs) of Class A common stock on 08/06/2025 under the company’s 2021 Incentive Award Plan, at a price of $0 as this is an equity award. Each RSU represents one share of Class A common stock and will vest at the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
The amendment corrects the number of shares beneficially owned to reflect the company’s 1-for-50 reverse stock split effective April 11, 2025, and to include certain indirectly owned securities. Following the correction, the director beneficially owns 6,331 Class A shares directly and 17,192 Class A shares indirectly through G&K Investment Holdings LLC, over which the director has voting and dispositive power.
P3 Health Partners Inc. director filed an amended insider trading report updating their share holdings after receiving a new equity grant. The director was granted 2,000 restricted stock units (RSUs) of Class A common stock on 08/06/2025 under the company’s 2021 Incentive Award Plan, at a price of $0 as this is an equity award. Each RSU represents one share of Class A common stock and will vest at the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
The amendment corrects the number of shares beneficially owned to reflect the company’s 1-for-50 reverse stock split effective April 11, 2025, and to include certain indirectly owned securities. Following the correction, the director beneficially owns 6,331 Class A shares directly and 17,192 Class A shares indirectly through G&K Investment Holdings LLC, over which the director has voting and dispositive power.
P3 Health Partners Inc. director reports updated stock grant details. A director received 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0, reflecting a standard equity award for board service. Each RSU converts into one share of Class A common stock and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date. After this grant, the director beneficially owns 6,331 Class A common shares directly.
This is an amended insider filing correcting the number of securities shown in Column 5 of Table I. The prior filing had inadvertently used the pre–reverse stock split amount instead of the post–split figure following the company’s 1-for-50 reverse stock split that became effective on April 11, 2025. The amendment is made solely to fix that post–split beneficial ownership number.
P3 Health Partners Inc. director reports updated stock grant details. A director received 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0, reflecting a standard equity award for board service. Each RSU converts into one share of Class A common stock and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date. After this grant, the director beneficially owns 6,331 Class A common shares directly.
This is an amended insider filing correcting the number of securities shown in Column 5 of Table I. The prior filing had inadvertently used the pre–reverse stock split amount instead of the post–split figure following the company’s 1-for-50 reverse stock split that became effective on April 11, 2025. The amendment is made solely to fix that post–split beneficial ownership number.